"Conotoxin Polypeptide K-Cptx-Bt102, and Method for Preparation Threof and Application Thereof" in Patent Application Approval Process. By a News Reporter-Staff News Editor at Drug Week A patent application by the inventors Lin, Zhilong; Wen, Bo; Tong, Ting; Liu, Jie; Du, Chaoqin; Mo, Fen; Peng, Chao; Shi, Qiong, filed on September 30, 2014, was
By a News Reporter-Staff News Editor at Drug Week A patent application by the inventor Margolin, David H., filed on May 10, 2017, was made available online on November 2, 2017, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application is assigned to Genzyme Corporation. The following quote wa
"New Indication of Cardiovascular Drugs for Preparation of Cancer Inhibition Pharmaceutical Composition" in Patent Application Approval Process. By a News Reporter-Staff News Editor at Drug Week A patent application by the inventors Chen, Chiu-Hung; Chuang, Show-Mei; Hsiao, Nai-Wan; Liang, Ruei-Yue; Tan, Xiao-Tong, filed on October 23, 2015, was
CAMBRIDGE, Mass.- Acceleron Pharma Inc., a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced new preclinical results with sotatercept in pulmonary arterial hypertension during an oral presentation at the American Heart Association 2017 Scientific Sessions.
BOTHELL, Wash and VANCOUVER, British Columbia- Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced results of a clinical study evaluating the effect of food on the bioavailability of 3 mg cytisine. Additionally, in preparati
NEW HAVEN- Achillion Pharmaceuticals, Inc. today reported preliminary proof-of-concept results from group 1 of its ongoing Phase 2, open-label, 14- day study of ACH-4471 for patients with C3 glomerulopathy or immune complex-mediated membranoproliferative glomerulonephritis. Tom Barbour, Royal Melbourne Hospital, Melbourne, Australia, Department of.
By a News Reporter-Staff News Editor at Drug Week Acorda Therapeutics, Inc. announced that Ron Cohen, M.D., Acorda's President and CEO, will present at the Stifel Healthcare Conference in New York on Wednesday, November 15, 2017 at 10:45 a.m. ET. A live audio webcast of the presentation can be accessed under "Investor Events" in the Investor sect
Under the Paperwork Reduction Act of 1995, Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the Gen
Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today presented updated data from the dose expansion cohort of the Phase 1 study evaluating single agent ivosidenib in patients with progressive low grade isocitrate dehydrogenase-1 mutant glioma. The data were presented today in a
By a News Reporter-Staff News Editor at Health& Medicine Week Allergan plc announced that it has received an Imported Drugs License from the Chinese Food and Drug Administration to market Ozurdex for the treatment of adult patients with macular edema following either Branch Retinal Vein Occlusion or Central Retinal Vein Occlusion.
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, today announced the company has initiated submission of a rolling New Drug Application to the U.S. Food and Drug Administration for patisiran, an investigational RNAi therapeutic targeting transthyretin, for the treatment of hereditary ATTR amyloidosis. The rolling submission all
AstraZeneca today announced that the US Food and Drug Administration has approved a new indication for FASLODEX, expanding the indication to include use with abemaciclib, a CDK4/6 inhibitor, for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2 negative advanced or metastatic breast cancer in women with disease...
AstraZeneca has announced that the US Food and Drug Administration has approved a new indication for Faslodex, expanding the indication to include use with abemaciclib, a CDK4/6 inhibitor, for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2 negative advanced or metastatic breast cancer in women with disease...
PETACH TIKVA, Israel Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced that its previously majority owned subsidiary OphthaliX, Inc. has successfully completed a merger with Wize Pharma Ltd.. As a result of the merger, C
Celyad, a clinical-stage biopharmaceutical company focused on the development of specialized CAR-T cell based therapies, today provided an update on key clinical and operational developments for the third quarter ended Sept. 30, 2017.. Reported first complete response by a CAR-T therapy in a patient with relapsed refractory AML in the Phase 1 b T
Cerecor Inc. and TRx Pharmaceuticals, LLC today announced that the companies have entered into a purchase agreement in which Cerecor will acquire TRx, including subsidiary Zylera Pharmaceuticals, LLC and its franchise of commercial medications led by Poly-Vi-Flor and Tri-Vi-Flor and a merger agreement in which Cerecor will acquire Zylera Phar
ChemoCentryx, Inc.,, a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer, today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Piper Jaffray 29 th Annual Healthcare Conference on Tuesday, November 28, 2017 at 1
Thanks in part to nearly two decades of research at Cincinnati Children's Hospital Medical Center, the FDA has approved benralizumab, the first drug designed to specifically deplete eosinophils as a treatment for asthma. The FDA approved benralizumab as an add-on maintenance treatment for severe asthma with eosinophil involvement.
By a News Reporter-Staff News Editor at Drug Week CMP Pharma announced that CaroSpir , the first and only FDA- approved oral liquid dosage form of the potassium-sparing diuretic spironolactone, is now available. CaroSpir was approved by the FDA on August 4, 2017 and is now available through normal retail distribution. CaroSpir is available in 1
NORWOOD, MA- Corbus Pharmaceuticals Holdings, Inc., a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that Yuval Cohen, Ph.D., Chief Executive Officer, will present at the 29th Annual Piper Jaffray Healthcare Conference on Tuesday, November 28, 2017 at 7:50 AM EST in New Y
Amir Kalali, will be interviewing Dr. William Carson, CEO of Otsuka Pharmaceutical Co., Ltd., and Andrew Thompson, president and CEO of Proteus Digital Health Eddie Martucci, CEO, and Adam Gazzaley, Chief Scientific Advisor, Akili Interactive Labs, and Bakul Patel, Center Director for Digital Health, FDA at CNS Summit 2017.. Otsuka and Proteus Digi
-As demand for DrugDev Spark continues to skyrocket worldwide, DrugDev, an IQVA company, will bring the groundbreaking unified clinical suite of proven solutions used on 2,000+ clinical trials in over 60 countries to Partnerships in Clinical Trials Europe, 28-29 November, RAI, Amsterdam. DrugDev executives and subject matter experts on hand will in
By a News Reporter-Staff News Editor at Drug Week Eagle Pharmaceuticals, Inc. announced that the United States Food and Drug Administration has granted tentative approval for the Company's PEMFEXY?, a pemetrexed injection ready-to-dilute formulation for locally advanced or metastatic nonsquamous non-small cell lung cancer in combination with...
AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the US Food and Drug Administration has approved FASENRA for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype. Pascal Soriot, Chief Executive Officer of AstraZeneca, said:' We'
By a News Reporter-Staff News Editor at Drug Week Indivior PLC announced that the Psychopharmacologic Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee of the U.S. Food and Drug Administration voted 18 to 1 to recommend approval of RBP-6000 for the treatment of opioid use disorder. "The Advisory Committees' favorabl